Clarivate Analytics have created the Cystic Fibrosis Disease Report, which provides an up-to-date assessment of the disease landscape, including its market size, an overview of the burden for clinical development, the competitive intensity of the current and future market, and its unmet medical needs.

The report includes data from Clarivate's flagship database, Cortellis, as well as our proprietary patient population forecast built around the company's Incidence & Prevalence Database, focusing on the US, the 5EU countries, Japan, and BRIC. Clarivate Analytics' analysts also provide their opinions on the development landscape, as well as promising therapies of interest. The report includes patient survey results and analysis provided by Raremark, a rare disease-focused patient advocacy network.

1. Disease background
2. Raremark patient survey
3. Digital health and devices
4. Cystic Fibrosis Transmembrane Receptor mutation classes
5. Therapeutic overview
6. Cystic Fibrosis transmembrane receptor modulator therapy - the competitive landscape
1. Vertex Pharmaceutical modulators
2. Proteostasis Therapeutics modulators
3. Select other modulators
7. Reimbursement
8. Gene therapy and gene editing
9. References